<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7254006\results\search\testTrace\results.xml">
  <result pre="and abiraterone as potential COVID-19 treatments with a robust two-tier" exact="screening" post="system YuanShuofengab1ChanJasper F.W.jfwchan@hku.hkabcd1*ChikKenn K.H.ab1ChanChris C.Y.abTsangJessica O.L.abLiangRonghuiabCaoJianliabTangKaimingabChenLin-LeiabWenKuneCaiJian-PiaoabYeZi-WeiabLuGangdfgChuHinabJinDong-YanhYuenKwok-Yungkyyuen@hku.hkabcd*[a], [b], [c], [d],"/>
  <result pre="more immediately available COVID-19 antivirals, we established a two-tier drug" exact="screening" post="system that combines SARS-CoV-2 enzyme-linked immunosorbent assay and cell"/>
  <result pre="and ivermectin. These results demonstrated the efficacy of the two-tier" exact="screening" post="system and identified potential COVID-19 treatments which can achieve"/>
  <result pre="human-pathogenic coronaviruses have emerged to cause epidemics of severe respiratory" exact="infection" post="among human, including severe acute respiratory syndrome coronavirus (SARS-CoV)"/>
  <result pre="globally [5]. The clinical severity of COVID-19 ranges from asymptomatic" exact="infection" post="to fatal disease. The disease is usually mild in"/>
  <result pre="disease. The disease is usually mild in children, but severe" exact="infection" post="in immunocompromised and elderly patients may be associated with"/>
  <result pre="pandemic is the lack of effective vaccine or antiviral for" exact="treatment" post="and prophylaxis. Similar to other emerging viral infections, the"/>
  <result pre="Chloroquine and hydroxychloroquine are mildly immunosuppressive drugs used in the" exact="treatment" post="of autoimmune diseases and malaria that exhibited 50 %"/>
  <result pre="and camostat are a serine protease inhibitor used in the" exact="treatment" post="of chronic pancreatitis and reflux esophagitis [14]. Ivermectin is"/>
  <result pre="esophagitis [14]. Ivermectin is a macrocyclic lactone used in the" exact="treatment" post="of various parasitic infections [15]. However, data from well-designed"/>
  <result pre="In this study, we first established a robust two-tier drug" exact="screening" post="system by combining SARS-CoV-2 enzyme-linked immunosorbent assay with cell"/>
  <result pre="evaluate the individual drug compoundsâ€™ cell protection effects against SARS-CoV-2" exact="infection" post="[21]. Briefly, VeroE6 cells seeded in 96-well plates were"/>
  <result pre="infected with SARS-CoV-2 for 1 h with 0.01 multiplicity of" exact="infection" post="(MOI), followed by washing with phosphate-buffered saline (PBS) and"/>
  <result pre="good cross-reactivity against SARS-CoV-2-N [17,23]. 2.4 FDA drug compound library" exact="screening" post="To identify anti-SARS-CoV-2 inhibitors, confluent VeroE6 cells in 96-well"/>
  <result pre="for 5 s and 55 Â°C for 30 s. Signal" exact="detection" post="and measurement were taken in each cycle after the"/>
  <result pre="the virus replication cycle, including: pre-treatment (From -2 h post" exact="infection" post="(hpi) to -1 hpi), co-infection with virus (-1 to"/>
  <result pre="3.1 Characterization of SARS-CoV-2 replication kinetics To develop a drug" exact="screening" post="system for SARS-CoV-2, we first characterized the viral replication"/>
  <result pre="observation of CPE development was recorded using different multiplicities of" exact="infection" post="(MOI) (1.000, 0.250, 0.063, 0.016, and 0.004). SARS-CoV-2 infection"/>
  <result pre="of infection (MOI) (1.000, 0.250, 0.063, 0.016, and 0.004). SARS-CoV-2" exact="infection" post="(MOI = 1.000) caused significant CPE in VeroE6 cells"/>
  <result pre="96-well plate were infected with SARS-CoV-2 of various multiplicities of" exact="infection" post="(MOIs)) as indicated, followed by phosphate buffered saline (PBS)"/>
  <result pre="a bright-field at 20Ã— magnification. (B) Cell viability of each" exact="treatment" post="group normalized with that of the mock-infected cells. (C)"/>
  <result pre="mean Â± standard deviation. 3.2 Establishment of a two-tier drug" exact="screening" post="system for rapid identification of antivirals against SARS-CoV-2 from"/>
  <result pre="laborious, and was thus inefficient as a high-throughput drug compound" exact="screening" post="assay. On the other hand, the ELISA (âˆ¼6 folds)"/>
  <result pre="of ELISA and cell viability assay as a two-tier drug" exact="screening" post="system for finding potential SARS-CoV-2 antivirals. This combinational screening"/>
  <result pre="drug screening system for finding potential SARS-CoV-2 antivirals. This combinational" exact="screening" post="system is rapid, non-labor-intensive, and can easily exclude false-positive"/>
  <result pre="20 Î¼L/well of cell culture supernatant was harvested for SARS-CoV-2-N" exact="detection" post="before addition of another 40 Î¼L/well CellTiter-GloÂ® substrate for"/>
  <result pre="identified 34 primary hit drug compounds with â‰¥4-fold reduction of" exact="detection" post="signal in ELISA. In the secondary screen by cell"/>
  <result pre="the study design. Using the newly established two-tier drug compound" exact="screening" post="system, an FDA-approved drug compound library consisting 1528 drug"/>
  <result pre="1528 drug compounds was screened for potential anti-SARS-CoV-2 agents. Primary" exact="screening" post="by ELISA identified 34 drug compounds with 4-fold reduction"/>
  <result pre="ELISA identified 34 drug compounds with 4-fold reduction in the" exact="detection" post="signal. Secondary screening by cell viability assay further selected"/>
  <result pre="drug compounds with 4-fold reduction in the detection signal. Secondary" exact="screening" post="by cell viability assay further selected 19 of the"/>
  <result pre="identified from an FDA-approved drug library with a two-tier drug" exact="screening" post="platform for SARS-CoV-2. Table 1 Compound Drug class Main"/>
  <result pre="(hydrochloride) Selective serotonin reuptake inhibitor Depression Micafungin (sodium) Echinocandin Fungal" exact="infection" post="Permethrin Insecticide Scabies and lice Pimavanserin Atypical antipsychotic Parkinsonâ€™s"/>
  <result pre="we included remdesivir as a comparator drug. Similar to remdesivir," exact="treatment" post="with any one of the four drug compounds below"/>
  <result pre="1 log to 3 logs. At 10Î¼M of drug concentration," exact="treatment" post="with cetilistat exhibited about 3 logs reduction at 48"/>
  <result pre="cell lysates (Fig. 5B). In addition to viral load reduction," exact="treatment" post="with any one of these four drug compounds provided"/>
  <result pre="compounds provided cell protection effects. In the CPE inhibition assay," exact="treatment" post="with 10Î¼M of cetilistat completely inhibited CPE development in"/>
  <result pre="were performed on SARS-CoV-2-infected (MOI = 0.100) VeroE6 cells after" exact="treatment" post="with cetilistat, diiodohydroxyquinoline, abiraterone acetate, or bexarotene (10Î¼M each)"/>
  <result pre="of these experiments. One-way ANOVA was used to compare the" exact="treatment" post="groups with the 0Î¼M (negative control) group. *P indicates"/>
  <result pre="mean Â± standard deviations. 4 Discussion The newly established two-tier" exact="screening" post="system in this study was robust and able to"/>
  <result pre="inhibitor that blocks fat digestion and absorption used in the" exact="treatment" post="of obesity [28]. Diiodohydroxylquinoline, also known as uidoquinol, is"/>
  <result pre="derivative that is used as a luminal amebicide for the" exact="treatment" post="of amoebiasis [29]. Cetilistat is rapidly hydrolyzed into its"/>
  <result pre="in SARS, feces might also be a potential source of" exact="infection" post="in COVID-19 [2,32]. Thus, besides being administered by inhalation,"/>
  <result pre="CYP17A1 [33,34]. Bexarotene is a third-generation retinoid used in the" exact="treatment" post="of cutaneous T cell lymphoma, non-small cell lung cancer,"/>
  <result pre="other human-pathogenic coronaviruses. In conclusion, the robust two-tier drug compound" exact="screening" post="system established in this study represented a novel platform"/>
  <result pre="coronavirus (2019-nCoV) in vitroCell Res.30202026927132020029 13GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt."/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect."/>
  <result pre="the subunits interaction of the viral polymeraseAntiviral Res.1252016344226593979 26ChanJ.F.YipC.C.ToK.K.TangT.H.WongS.C.LeungK.H.FungA.Y.NgA.C.ZouZ.TsoiH.W.Improved molecular" exact="diagnosis" post="of COVID-19 by the novel, highly sensitive and specific"/>
  <result pre="lipase inhibitor cetilistat in healthy volunteersBr. J. Clin. Pharmacol.67200930931519220279 29RickardsA.G.The" exact="treatment" post="of amoebiasis with diodoquinJ. Trop. Med. Hyg.521949333818111812 30PadwalR.Cetilistat, a"/>
  <result pre="Trop. Med. Hyg.521949333818111812 30PadwalR.Cetilistat, a new lipase inhibitor for the" exact="treatment" post="of obesityCurr. Opin. Investig. Drugs92008414421 31CheungK.S.HungI.F.ChanP.P.LungK.C.TsoE.LiuR.NgY.Y.ChuM.Y.ChungT.W.TamA.R.Gastrointestinal manifestations of SARS-CoV-2"/>
  <result pre="treatment of obesityCurr. Opin. Investig. Drugs92008414421 31CheungK.S.HungI.F.ChanP.P.LungK.C.TsoE.LiuR.NgY.Y.ChuM.Y.ChungT.W.TamA.R.Gastrointestinal manifestations of SARS-CoV-2" exact="infection" post="and virus load in fecal samples from the Hong"/>
 </snippets>
</snippetsTree>
